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Abstract
Background and Objective Lysergic acid diethylamide
(LSD) is used recreationally and in clinical research. The
aim of the present study was to characterize the pharma-
cokinetics and exposure–response relationship of oral LSD.
Methods We analyzed pharmacokinetic data from two
published placebo-controlled, double-blind, cross-over
studies using oral administration of LSD 100 and 200 lg in
24 and 16 subjects, respectively. The pharmacokinetics of
the 100-lg dose is shown for the first time and data for the
200-lg dose were reanalyzed and included. Plasma con-
centrations of LSD, subjective effects, and vital signs were
repeatedly assessed. Pharmacokinetic parameters were
determined using compartmental modeling. Concentration-
effect relationships were described using pharmacokinetic-
pharmacodynamic modeling.
Results Geometric mean (95% confidence interval) maxi-
mum plasma concentration values of 1.3 (1.2–1.9) and 3.1
(2.6–4.0) ng/mL were reached 1.4 and 1.5 h after admin-
istration of 100 and 200 lg LSD, respectively. The plasma
half-life was 2.6 h (2.2–3.4 h). The subjective effects las-
ted (mean ± standard deviation) 8.2 ± 2.1 and
11.6 ± 1.7 h for the 100- and 200-lg LSD doses, respec-
tively. Subjective peak effects were reached 2.8 and 2.5 h
after administration of LSD 100 and 200 lg, respectively.
A close relationship was observed between the LSD con-
centration and subjective response within subjects, with
moderate counterclockwise hysteresis. Half-maximal
effective concentration values were in the range of 1 ng/
mL. No correlations were found between plasma LSD
concentrations and the effects of LSD across subjects at or
near maximum plasma concentration and within dose
groups.
Conclusions The present pharmacokinetic data are
important for the evaluation of clinical study findings (e.g.,
functional magnetic resonance imaging studies) and the
interpretation of LSD intoxication. Oral LSD presented
dose-proportional pharmacokinetics and first-order elimi-
nation up to 12 h. The effects of LSD were related to
changes in plasma concentrations over time, with no evi-
dence of acute tolerance.
Trial registration: NCT02308969, NCT01878942.
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Key Points
The pharmacokinetics of lysergic acid diethylamide
was dose proportional and the subjective effects
were related to the time course of plasma
concentrations within subjects, with no evidence of
acute tolerance.
Between-subject differences in plasma
concentrations of lysergic acid diethylamide did not
predict the subjective response within a dose group
and when plasma concentrations were above the
half-maximal effective concentration of the response
measures.
1 Introduction
Lysergic acid diethylamide (LSD) is the prototypical hal-
lucinogen [1, 2]. Lysergic acid diethylamide has seen
worldwide interest with regard to pharmacology, psychia-
try, and society at large. Lysergic acid diethylamide con-
tinues to be used for recreational and personal purposes [3].
Additionally, considerable interest has been seen in its
therapeutic potential [4–9], and experimental clinical
research with LSD has recently been reinitiated [10–23].
However, basic pharmacokinetic information on LSD is
largely missing. A small study in five male subjects
reported a mean plasma elimination half-life of LSD of
175 min after intravenous administration (2 lg/kg) [24].
Another non-systematic study sampled blood after admin-
istration of LSD 160 lg in 13 subjects up to 2.5–5 h but
because of sparse and short sampling could not derive
pharmacokinetic parameters [25]. We recently reported the
first pharmacokinetic data for orally administered LSD
(200 lg) in 16 male and female subjects [23]. The con-
centrations of LSD were maximal after 1.5 h (median) and
gradually declined to very low levels by 12 h, with an
elimination half-life of 3.6 h [23].
Recent studies have reported the effects of LSD on
various neuronal correlates of brain activation
[12, 13, 16, 17]. However, plasma exposure and thus the
actual presence of LSD in the body have not been docu-
mented in any of these studies to date. Unknown are the
time point at which peak concentrations are reached and
the actual or predicted concentrations of LSD at the time
point at which pharmacodynamic outcomes were collected.
Therefore, the primary goal of the present study was to
describe the pharmacokinetics of a controlled administra-
tion of oral LSD by assessing the plasma concentration-
time profile of two doses of LSD (100 and 200 lg). A
second goal was to link the plasma concentration changes
over time within subjects to the acute subjective and
autonomic effects of LSD to derive half-maximal effective
concentration (EC50) values using standard pharmacoki-
netic-pharmacodynamic modeling.
Researchers have correlated subjective drug effects with
brain functional magnetic resonance imaging (fMRI) data
[12, 13, 16, 17]. This approach likely detects significant
correlations for subjective effects that show large between-
subject variance but not for subjective effects of the sub-
stance that are consistently present in all subjects. Plasma
concentrations of LSD have not been determined in any of
the published LSD fMRI studies to date; therefore, it is
unclear how LSD exposure in the body is linked to sub-
jective effects in these studies. Therefore, a further goal of
the present study was to assess associations across subjects
between plasma exposure to LSD and the pharmacody-
namic effects at corresponding times.
The present study combined data from two similar
clinical studies that tested 100- and 200-lg doses of LSD in
24 and 16 healthy subjects, respectively. The pharma-
cokinetic data and concentration–effect relationship of
100 lg LSD are presented. Similar data on 200 lg LSD
have been previously reported [23]. In the present study,
plasma concentrations after 200 lg LSD administration
were newly measured using a more sensitive and specific
analytical method. The results were included for compar-
isons with the 100-lg data and to newly evaluate
dose/concentration–response effects. The subjective effects
of LSD have been reported for both doses, but relationships
to plasma exposure were not evaluated [21].
2 Methods
2.1 Study Design
We performed the pharmacokinetic data analysis on two
similar previously performed studies [21–23] using double-
blind, placebo-controlled, cross-over designs with two
experimental test sessions (LSD and placebo) in a balanced
order. Study 1 used a dose of LSD 100 lg and placebo in
24 subjects. Study 2 used LSD 200 lg and placebo in 16
subjects. The washout periods between sessions were at
least 7 days. The studies were registered at ClinicalTri-
als.gov (NCT02308969, NCT01878942).
2.2 Participants
Forty healthy participants were recruited from the
University of Basel campus via an online advertisement.
Twenty-four subjects [12 men, 12 women; age
33 ± 11 years (mean ± standard deviation); range
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25–60 years; body weight: 68 ± 8 kg, 55–85 kg) partici-
pated in Study 1 (100 lg), and 16 subjects (eight men,
eight women; age 29 ± 6 years; range 25–51 years; body
weight: 72 ± 12 kg, 52–98 kg) participated in Study 2
(200 lg). The inclusion and exclusion criteria were iden-
tical for both studies. The exclusion criteria were
age\25 years or[65 years, pregnancy (urine pregnancy
test at screening and before each test session), personal or
family (first-degree relative) history of major psychiatric
disorders (assessed by the semi-structured clinical inter-
view for Diagnostic and Statistical Manual of Mental
Disorders, 4th edition, Axis I disorders by the study
physician and an additional interview by a trained psy-
chiatrist), use of medications that may interfere with the
study drug, chronic or acute physical illness (abnormal
physical examination, electrocardiogram, or hematological
and chemical blood analyses), tobacco smoking (more than
ten cigarettes/day), lifetime prevalence of illicit drug use
more than ten times (except for tetrahydrocannabinol),
illicit drug use within the previous 2 months, and illicit drug
use during the study. We performed urine drug tests at
screening and before each test session, and no substances
were detected during the study. The subjects were asked to
abstain from excessive alcohol consumption between test
sessions and particularly limit their use to one standard drink
on the day before the test sessions. Additionally, the par-
ticipants were not allowed to drink xanthine-containing
liquids after midnight before the study day. The participants
did not regularly use medications that could potentially
interact with the study drug. No other medications aside
from LSD were used during the study sessions. Eleven
subjects had previously used a hallucinogen, including LSD
(six participants), one to three times during their lives, and
most of the subjects (29) were hallucinogen naive.
2.3 Study Procedures
Each study included a screening visit, a psychiatric inter-
view, two 25-h experimental sessions, and an end-of-study
visit. The experimental sessions were conducted in a quiet
standard hospital patient room. The participants were resting
in hospital beds except when going to the restroom. Only one
research subject and one investigator were present during
the experimental sessions. The participants could interact
with the investigator, rest quietly, and/or listen to music via
headphones, but no other entertainment was provided. LSD
or placebo was administered at 9:00 A.M. A standardized
lunch and dinner was served at 1:30 P.M. and 5.30 P.M.,
respectively. The subjects were never alone during the first
12 h after drug administration, and the investigator was in a
room next to the subject for up to 24 h while the subject was
asleep (mostly from 1:00 A.M. to 8:00 A.M.).
2.4 Study Drug
Lysergic acid diethylamide (d-lysergic acid diethylamide
hydrate, high-performance liquid chromatography pur-
ity[99%; Lipomed AG, Arlesheim, Switzerland) was
administered in a single oral dose of 100 or 200 lg as a
capsule (Bichsel Laboratories, Interlaken, Switzerland).
Both doses were within the range of doses that are taken for
recreational purposes [1]. The 200-lg dose (the same
capsules) was also used in LSD-assisted psychotherapy in
patients [6], and intravenous doses of 75–100 lg have been
used in fMRI studies in healthy subjects [13].
2.5 Measures
2.5.1 Blood Sampling
Blood was collected into lithium heparin tubes before and
0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, and 24 h after LSD
administration. The 0.5-, 1.5-, and 2.5-h samples were not
collected in Study 1 (100 lg). The blood samples were
immediately centrifuged, and the plasma was rapidly stored
at -20 C and later at -80 C until analysis within
12 months. Long-term stability has been shown for LSD
when kept under refrigerated or frozen conditions [26, 27].
Samples were thawed for the first time for both analyses,
this was also the case for study 2 (200 lg) because separate
sets of samples were stored and used for the present [28]
and previous [29] analyses.
2.5.2 Analysis of Lysergic Acid Diethylamide
Concentrations
Lysergic acid diethylamide concentrations in plasma were
determined using sensitive and validated liquid chro-
matography-tandem mass spectrometry methods as repor-
ted in detail elsewhere [28, 29]. The lower limit of
quantification was 0.05 ng/mL in Study 1 (100 lg) [29]
and 0.01 ng/mL in Study 2 (200 lg) [28].
2.5.3 Subjective Mood
Visual analog scales (VASs) were repeatedly used to assess
subjective effects over time [21, 22]. The VASs included
separate measures for ‘‘any drug effect,’’ ‘‘good drug
effect,’’ and ‘‘bad drug effect’’ and were presented as
100-mm horizontal lines (0–100%) marked from ‘‘not at
all’’ on the left to ‘‘extremely’’ on the right. The VASs
were administered 1 h before and 0, 0.5, 1, 1.5, 2, 2.5, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 16, and 24 h after drug adminis-
tration. The 0.5- and 2.5-h ratings were not collected in
Study 1 (100 lg).
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2.5.4 Vital Signs
Blood pressure, heart rate, and body temperature were
assessed repeatedly 1 h before and 0, 0.5, 1, 1.5, 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12, and 24 h after drug administration.
Diastolic and systolic blood pressure and heart rate were
measured using an automatic oscillometric device
(OMRON Healthcare Europe NA, Hoofddorp, Nether-
lands). The measurements were performed in duplicate at
an interval of 1 min and after a resting time of at least
10 min. The averages were calculated for analysis. Core
(tympanic) temperature was measured using a GENIUSTM
2 ear thermometer (Tyco Healthcare Group LP, Water-
town, NY, USA). The 0.5- and 2.5-h measures were not
collected in Study 1 (100 lg).
2.6 Pharmacokinetic Analyses
and Pharmacokinetic-Pharmacodynamic
Modeling
All of the analyses were performed using Phoenix
WinNonlin 6.4 (Certara, Princeton, NJ, USA). Pharma-
cokinetic parameters were estimated using compartmental
modeling. A one-compartment model was used with first-
order input, first-order elimination, and no lag time. Initial
estimates for apparent volume of distribution and k were
derived from non-compartmental analyses.
The model fit was not relevantly improved by a two-
compartment model based on visual inspection of the plots.
The one-compartment model showed better Akaike infor-
mation criterion values in all subjects than a two-com-
partment model. The pharmacokinetic model was first
fitted and evaluated. The predicted concentrations were
then used as inputs to the pharmacodynamic model, treat-
ing the pharmacokinetic parameters as fixed and using the
classic pharmacokinetic/pharmacodynamic link model
module in WinNonlin. The model uses a first-order equi-
librium rate constant (keo) that related the observed phar-
macodynamic effects of LSD to the estimated LSD
concentrations at the effect site (Fig. S1) and accounts for
the lag between the plasma- and effect-site concentration
curves [30]. Initial estimates for keo values were obtained
using semi-compartmental modeling by collapsing the
hysteresis loop in the Ce vs. effect plots in WinNonlin. A
sigmoid maximum effect (Emax) model (EC50, Emax, c) was
selected for all pharmacodynamic effects. EC50 and Emax
estimates were taken from the pharmacokinetic-pharma-
codynamic plots. Lower and upper limits for Emax were set
to 0 and 100%, respectively, for all the VAS scores. Upper
limits for Emax for changes in heart rate, body temperature,
and diastolic and systolic blood pressure were set to
100/min, 2 C, 50 and 80 mm Hg, respectively. The sig-
moidal Emax model best described the relationship between
estimated effect-site concentrations and the effects of LSD
compared with a simple Emax model (plot inspection and
Akaike information criteria). Examples of diagnostic plots
are shown in Figs. S8 and S9.
2.7 Statistical Analyses
The LSD-induced subjective and autonomic effects were
determined as a difference from placebo in the same sub-
ject at the corresponding time point to control for circadian
changes and placebo effects [22]. The pharmacodynamic
effect changes after LSD administration for each time point
were plotted over time (effect-time curves) and against the
respective plasma concentrations of LSD and graphed as
concentration-effect curves. The onset, time to maximum
plasma concentration (Tmax), offset, and effect duration
were assessed for the model-predicted ‘‘any drug effect’’
VAS effect-time plots after LSD using a threshold of 10%
of the maximal possible effect of 100% using Phoenix
WinNonlin 6.4. Associations between concentrations and
effects were assessed using Pearson correlations, and
multiple regression analysis was used to exclude effects of
sex and body weight (Statistica 12 software; StatSoft,
Tulsa, OK, USA).
3 Results
3.1 Pharmacokinetics
The plasma concentration-time curves for the two LSD
doses are shown in Fig. 1a. The pharmacokinetic parame-
ters are shown in Table 1. In Study 1 (100 lg), LSD could
be quantified up to 8, 10, 12, 16, and 24 h in 24, 23, 22, 9,
and one subject, respectively. In Study 2 (200 lg), LSD
could be quantified up to 16 h in all 16 subjects and up to
cFig. 1 Pharmacokinetics and pharmacodynamics of lysergic acid
diethylamide (LSD). a LSD plasma concentration-time curves. The
corresponding semi-log plot is shown in Fig. S3. LSD effect-time
curves for Visual Analog Scale ratings (0–100%) of b ‘‘any drug
effect,’’ d ‘‘good drug effect,’’ and f ‘‘bad drug effect.’’ c, e, g In the
LSD concentration-effect plots (hysteresis curves), the subjective
effects of LSD showed moderate counterclockwise hysteresis,
indicating a relatively short delay in the effect of LSD relative to
the changes in plasma concentration over time. The plasma concen-
tration-effect site equilibration half-lives were in the range of
21–48 min according to the pharmacokinetic-pharmacodynamic link
model (Table 2). ‘‘Any drug effect’’ and ‘‘good drug effect’’ were
robustly and markedly increased in all subjects and paralleled the
changes in LSD concentration, whereas the mean ‘‘bad drug effect’’
increased only moderately after LSD owing to transient increases.
‘‘Bad drug effect’’ occurred mostly at the onset of the drug effect in
some subjects but also later in time in others. The data are expressed
as the mean ± standard error of the mean in 24 and 16 subjects after
administration of 100 and 200 lg LSD, respectively. The time of
sampling is noted next to each point. LSD was administered at t = 0
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24 h in 15 subjects (Fig. S2). Mean maximum plasma
concentration (Cmax) and area under the concentration-time
curve values were approximately twice as high for the
200-lg dose compared with the 100-lg dose. Dose-nor-
malized Cmax and area under the concentration-time curve
values were not statistically different between the dose
groups and the Tmax and plasma half-lives were also sim-
ilar, consistent with dose-proportional pharmacokinetics
(Table 1). Consistent with the fit of the one-compartment
model, inspection of the semi-logarithmic concentration-
time curves showed linear elimination kinetics for both
doses (Fig. S3) up to 12 h as previously reported for the
200-lg dose [23]. The individual-observed and model-
predicted LSD concentrations are shown in Fig. S2. Plasma
concentrations varied considerably between subjects,
especially at the lower 100-lg dose (Table 1; Fig. S2).
3.2 Pharmacodynamics
Lysergic acid diethylamide produced robust increases in
‘‘any drug effect’’ (Fig. 1b, Fig. S4) and ‘‘good drug
effect’’ (Fig. 1d, Fig. S5). Transient ‘‘bad drug effect’’ was
reported in some subjects, resulting in a moderate increase
in mean group ratings (Fig. 1f, Fig. S6). The corresponding
subjective peak effects have previously been reported and
were shown to be dose dependent [21]. ‘‘Any drug effect,’’
‘‘good drug effect,’’ and ‘‘bad drug effect’’ ratings for each
subject are shown in Figs. S4–6, respectively. After
administration of the 100-lg dose of LSD, the times of
onset and offset of the subjective response, assessed by the
‘‘any drug effect’’ VAS, were (mean ± standard deviation)
0.8 ± 0.4 h (range 0.1–1.7 h) and 9.0 ± 2.0 h (range
6.1–14.5 h), respectively. The mean effect duration was
8.2 ± 2.1 h (range 5–14 h). The time to peak drug effect
was 2.8 ± 0.8 h (range 1.2–4.6 h). After administration of
the 200-lg dose of LSD, the times of onset and offset of
the subjective response were 0.4 ± 0.3 h (range
0.04–1.2 h) and 11.6 ± 4.2 h (range 7.0–19.5 h), respec-
tively. The mean effect duration was 11.2 ± 4.2 h (range
6.4–19.3 h). The time to the subjective peak response was
2.5 ± 1.2 h (range 0.8–4.4 h). LSD increased diastolic and
systolic blood pressure, heart rate, and body temperature
compared with placebo to similar extents for both doses
(Fig. 2). The corresponding peak effect data and dose-re-
sponse statistics have been previously reported [21].
3.3 Pharmacokinetic-Pharmacodynamic Modeling
Figures 1 and 2 show the subjective, cardiovascular, and
thermogenic effects of LSD plotted against the plasma
concentration over time. A close relationship was found
between LSD concentrations and LSD effects over time.
Counterclockwise hysteresis was observed during the
assumed drug distribution phase (\2 h), especially for
body temperature (Fig. 2h). Model-predicted effects of
LSD on the VASs for ‘‘any drug effect,’’ ‘‘good drug
effect,’’ and ‘‘bad drug effect’’ are illustrated for each
subject in Figs. S4–6, respectively. Table 2 shows the
predicted concentrations of LSD at the effect site that
produced half-maximal effects (EC50 values). Mean EC50
Table 1 Pharmacokinetic parameters for LSD based on compartmental modeling
Dose N k01 (1/h) k (1/h) Vd (L) Cmax (ng/
mL)
tmax (h) t1/2 (h) AUC?
(ngh/mL)
CL/F (L/h)
100 lg 24 Geometric mean
(95% CI)
1.4
(1.2–4.1)
0.27
(0.24–0.31)
46
(35–76)
1.3
(1.2–1.9)
1.4
(1.3–2.1)
2.6
(2.4–3.0)
8.1
(7.5–11.1)
12.3
(7.8–24)
Range 0.31–9.9 0.17–0.50 24–270 0.3–3.7 0.4–3.2 1.4–4.2 1–19 5.2–103
200 lg 16 Geometric mean
(95% CI)
1.2
(0.68–4.6)
0.27
(0.22–0.35)
37
(32–46)
3.1
(2.6–4.0)
1.5
(1.3–2.4)
2.6
(2.2–3.4)
20.3
(17.3–26.2)
9.9
(8.3–12.8)
Range 0.27–10 0.12–0.59 18–66 1.9–7.1 0.4–3.8 1.2–5.6 11–39 5.1–18.5
AUC? area under the plasma concentration-time curve from time zero to infinity, Cmax estimated maximum plasma concentration, t1/2 estimated
plasma elimination half-life, tmax estimated time to reach Cmax, k01 first-order absorption coefficient, k first order elimination coefficient, Vd
volume of distribution
cFig. 2 Pharmacokinetics and autonomic effects in response to
lysergic acid diethylamide (LSD). The figure shows LSD effect-time
curves for a diastolic blood pressure, c systolic blood pressure, e heart
rate, and g changes in body temperature and corresponding b, d, f,
h LSD concentration-effect plots (hysteresis curves). The cardiovas-
cular stimulant effects of LSD at the higher 200-lg dose showed only
little counterclockwise hysteresis, indicating a short delay in the
effect of LSD relative to the changes in plasma concentration over
time and thus a close relationship between LSD concentration and
changes in cardiovascular effects over time within subjects. The
plasma concentration-effect site equilibration half-lives were in the
range of 13–34 min according to the pharmacokinetic-pharmacody-
namic link model (Table 2). In contrast, marked counterclockwise
hysteresis was observed in the LSD concentration-body temperature
change plot, indicating that the LSD-induced changes in body
temperature manifested themselves slowly and with a mean plasma
concentration-effect site equilibration half-life of 136 min for the
200-lg dose (Table 2). The data are expressed as the mean ± stan-
dard error of the meant in 24 and 16 subjects after administration of
LSD 100 and 200 lg, respectively. The pharmacodynamic values are
the mean ± standard error of the mean differences from placebo at
each time point. The time of sampling is noted next to each point.
LSD was administered at t = 0
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values were in the range of 0.67–2.5 ng/mL and lower for
‘‘good drug effect’’ than for ‘‘bad drug effect’’ (Table 2).
‘‘Any drug effect’’ and ‘‘good drug effect’’ could be
modeled in all of the subjects, whereas no ‘‘bad drug
effect’’ (ratings \5% at any time point) was reported in
eight (33%) and five (31%) subjects after 100 and 200 lg,
respectively. Thus, the EC50 and keo values could not be
determined in these subjects. Similarly, vital signs did not
change sufficiently in a few subjects (one to three/outcome)
to determine these values.
The predicted Cmax of LSD did not correlate with the
predicted maximal response on the ‘‘any drug effect’’ VAS
when analyzed across subjects and separately for the two
dose groups (Rp = 0.38, p = 0.08, and Rp = 0, p = 0.9,
for the 100- and 200-lg doses, respectively). There was a
significant correlation in the pooled sample (Rp = 0.38,
p\ 0.05, n = 40, Fig. S7). The predicted area under the
concentration-time curve of LSD did not correlate with the
predicted area under the concentration-time curve for ‘‘any
drug effect’’, a measure of the overall pharmacodynamic
response (Rp = 0, p = 0.9, and Rp = 0.27, p = 0.4,
respectively). Additionally, there were generally no corre-
lations between plasma LSD concentrations and different
pharmacodynamic effects for matched time points across
subjects within dose groups (Table 3). A few correlations
were significant at the beginning (1 h) and end (8 and 12 h)
of the LSD effect. However, no significant associations
were found between plasma concentrations and effects
during the peak response to LSD (3–6 h). Multiple
regression analysis, including LSD concentration, body
weight, and sex, revealed no associations between the
effects of LSD and any of these possible predictors. Thus,
the plasma concentrations of LSD did not predict the
effects of LSD during the time it produced robust and
similar effects in all of the subjects (i.e., little between-
subject variability). In contrast, a close relationship was
found over time within subjects, as shown in the pharma-
cokinetic-pharmacodynamic analysis (Figs. 1, 2).
4 Discussion
The present study describes the pharmacokinetics and
concentration–effect relationship after oral administration
of LSD 100 lg. Additionally, the previously reported
pharmacokinetics and concentration–effect relationship for
the 200-lg dose of LSD [23] were reanalyzed and included
for comparison with the 100-lg dose. Compartmental
modeling predicted geometric mean peak plasma concen-
trations of 1.3 ng/mL, 1.4 h after administration of the
100-lg dose. Mean Cmax values of 3.1 ng/mL were reached
after 1.5 h after administration of the 200-lg dose. The
predicted mean half-lives of LSD were 2.6 h after both
doses. The plasma half-life in the present study was com-
parable to the value of 2.9 h after intravenous administra-
tion of 2 lg/kg of LSD [24] but shorter than the 3.6-h value
previously determined using non-compartmental analysis
[23]. Additionally, the plasma concentrations after admin-
istration of the 200-lg dose in the present study were lower
than those that were previously published in the same
research subjects [23]. This can be explained by the dif-
ferent analytical methods and modeling approach that were
Table 2 Pharmacodynamic parameter estimates (PK-PD link model)
Effect Dose EC50 (ng/mL) Emax (%) c keo (1/h) T1/2keo (min)
Any drug effect 100 lg 0.75 ± 0.4 95 ± 9 4.2 ± 1.2 1.8 ± 1.3 35 ± 23
200 lg 1.2 ± 0.7 97 ± 5 3.4 ± 1.5 3.4 ± 1.7 21 ± 17
Good drug effect 100 lg 0.71 ± 0.5 89 ± 15 3.9 ± 1.5 2.0 ± 1.6 39 ± 37
200 lg 0.94 ± 0.5 93 ± 9 3.2 ± 1.6 2.4 ± 1.8 32 ± 29
Bad drug effect 100 lg 1.5 ± 1.1 32 ± 37 4.7 ± 2.3 2.7 ± 2.2 42 ± 37
200 lg 2.5 ± 1.6 34 ± 35 3.2 ± 2.1 2.8 ± 2.0 48 ± 66
Heart rate increase 100 lg 0.67 ± 0.5 22 ± 25 3.7 ± 2.0 2.5 ± 1.9 46 ± 52
200 lg 1.9 ± 1.2 33 ± 28 2.7 ± 1.8 4.0 ± 2.0 13 ± 8
Body temperature increase 100 lg 0.75 ± 0.4 1.1 ± 0.6 2.2 ± 1.8 1.5 ± 1.6 107 ± 121
200 lg 1.8 ± 1.1 1.0 ± 0.6 3.6 ± 2.0 1.7 ± 1.9 136 ± 155
Diastolic blood pressure increase 100 lg 0.9 ± 0.6 23 ± 14 2.0 ± 1.6 2.6 ± 1.9 53 ± 70
200 lg 1.6 ± 0.9 18 ± 11 3.5 ± 1.6 3.4 ± 1.9 31 ± 42
Systolic blood pressure increase 100 lg 0.8 ± 0.5 30 ± 17 1.9 ± 1.6 2.6 ± 1.7 51 ± 78
200 lg 1.9 ± 1.4 30 ± 17 2.9 ± 1.9 3.2 ± 1.9 34 ± 41
Values are means ± standard deviations. T1/2keo = ln2/keo, calculated for each individual value
EC50 maximal effect predicted by the PK-PD link model, EC50 predicted drug concentration at effect site producing a half-maximal effect, c
sigmoid shape parameter, keo first-order rate constant for the equilibration process between plasma concentration and effect site (PK-PD model
link parameter), t1/2keo (min) plasma-effect-site equilibration half-life
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used in the present study, which predicts lower Cmax values
than the observed values. Overall, we observed linear dose
and elimination kinetics of LSD up to 12 h after drug
administration.
The present data on the plasma concentration-time
curves of LSD are important because many experimental
and therapeutic studies are currently being conducted or
have been published without this detailed information on
the presence of LSD in the human body. Specifically, the
effects of LSD on emotion processing after 100 and 200 lg
have been reported [23], but no pharmacokinetic data were
reported. Additionally, fMRI data were obtained in Study 1
(100 lg) in Basel and in an additional study in Zurich
(n = 22) that did not perform blood sampling. Doses of
100 lg were used in both studies. Thus, the present study
provides estimates of LSD concentrations in plasma over
time for these studies and the observed and predicted time
courses of the subjective and autonomic effects of LSD.
The 200-lg dose preparation of LSD has been used in
patients [5, 6], and the present phase I study provides the
pharmacokinetic data for these phase II studies.
In contrast, no data are currently available on the plasma
concentrations of LSD after intravenous administration of
75 lg of LSD base in saline [11], despite the publication of
extensive pharmacodynamic data using this preparation
and route of administration [10–19]. The intravenous 75-lg
dose of LSD produced comparably strong alterations in
consciousness to the 100-lg dose in the present study
[10, 31]. Additionally, the time-concentration curve for the
75-lg intravenous preparation remains unknown. Specifi-
cally, an intravenous bolus dose of LSD would be expected
to result in peak effects shortly after administration.
Indeed, early studies reported that intravenous adminis-
tration of LSD tartrate salt at a higher dose (2 lg/kg of
base) produced a rapid onset within seconds to minutes and
peak effects that occurred approximately 30 min after
administration [24, 32–34].
In the more recent studies that used the 75-lg dose
administered as the base, subjective drug effects reportedly
began within 5–15 min and peaked 45–90 min after
intravenous dosing, although further details were not
reported [13, 19]. Other hallucinogens with mechanisms of
action that are similar to those of LSD (e.g., serotonin
5-HT2A receptor stimulation [35]), such as dimetyl-
tryptamine or psilocybin, also produced subjective and
autonomic effects almost instantaneously and peak effects
within 2–5 min after intravenous administration [36–38].
In the present study, the mean effect onset and peak were
48 and 170 min, respectively, after oral administration of
LSD 100 lg. Thus, the effect began and peaked an average
Table 3 Correlations between plasma levels of LSD and its pharmacodynamic effects at the corresponding time points after administration
Effect 1 h 2 h 3 h 4 h 6 h 8 h 10 h 12 h
Any subjective drug effect 100 lg N = 24 0.17 0.13 -0.02 -0.04 -0.18 0.09 0.01 -0.03
200 lg N = 16 0.21 0.17 0.1 0.13 0.2 0.16 0.33 0.42
Both N = 40 0.36 0.35 0.19 0.04 0.06 0.41 0.46 0.49
Good drug effect 100 lg N = 24 0.6 0.3 0.23 0.15 -0.13 -0.2 -0.03 0.04
200 lg N = 16 0 -0.23 0.32 0.27 0.28 0.55 0.39 0.17
Both N = 40 0.39 0.34 0.36 0.31 0.24 0.42 0.35 0.23
Bad drug effect 100 lg N = 24 0.06 -0.11 -0.23 -0.1 -0.08 -0.03 0 -0.15
200 lg N = 16 0.34 -0.32 -0.27 0.07 0.2 0.35 -0.26 -0.16
Both N = 40 0.36 -0.16 0 0 0.1 0.29 0.05 0.07
Heart rate increase 100 lg N = 24 0.41 0.3 0.4 0.27 0.1 0.26 -0.4 0.027
200 lg N = 16 0.3 0.21 0.3 -0.06 -0.08 0.19 -0.16 -0.52
Both N = 40 0.44 0.41 0.33 0.08 -0.05 -0.02 0.03 -0.2
Body temperature increase 100 lg N = 24 0.12 -0.27 0.14 0.07 0.18 -0.06 -0.2 0.41
200 lg N = 16 0.09 -0.11 0.54 -0.1 -0.02 0.37 0.15 -0.19
Both N = 40 -0.08 -0.18 0.25 -0.15 -0.09 -0.12 0.02 0.06
Diastolic blood pressure increase 100 lg N = 24 0.16 -0.09 0.14 0.04 0.17 0.15 0.28 0.13
200 lg N = 16 -0.53 -0.22 0.2 -0.13 0.09 0.27 0.09 0.47
Both N = 40 -0.2 -0.03 0.07 0.03 -0.06 -0.01 0.01 0.07
Systolic blood pressure increase 100 lg N = 24 0.1 0.05 0.06 0 0.2 0.23 0.29 0.21
200 lg N = 16 -0.03 -0.4 -0.1 0.25 0 0.54 -0.02 0.19
Both N = 40 0 0.07 0.03 0.07 -0.07 0.11 0.05 0.08
Data are Pearson correlation coefficients between the LSD concentration in plasma and the corresponding time-matched effect of LSD. Bold
values indicate significant associations (p\ 0.05)
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of 30 and 100 min later, respectively, after oral adminis-
tration compared with intravenous administration of an
equivalent dose [13, 19]. Magnetic resonance imaging
scanning correctly started at approximately 70 and 150 min
in the studies that used intravenous [13] and oral (unpub-
lished data from Study 1, 100 lg) routes of LSD admin-
istration, respectively, coinciding with the maximal
response to LSD. Nevertheless, the plasma concentrations
of LSD and associated time-matched subjective responses
after intravenous LSD administration should also be
determined to better evaluate the considerable research
data that have been generated with this formulation.
After intravenous administration, a drug is rapidly
diluted and distributed within the blood. Peak plasma
concentrations are typically reached rapidly, and elimina-
tion begins immediately. Using the model parameters k and
keo from the present study, the Tmax for ‘‘any drug effect’’
after intravenous administration can be predicted to occur
at approximately 70 and 50 min for the 100- and 200-lg
doses and are thus similar to the recently observed times to
peak effects [13, 19]. In our model, the relatively long Tmax
of the effect of LSD is represented by the lag that is
attributable to distribution of the drug from plasma to the
hypothetical effect compartment. The cause for this lag is
unclear. Additional studies are needed to determine whe-
ther LSD is distributed slowly because it is present only in
small concentrations or slowly penetrates the blood–brain
barrier or whether there is a lag in the response mechanism.
The present study showed that LSD produced robust and
high subjective ‘‘any drug effect’’ and ‘‘good drug effect’’
in almost all of the subjects. The estimates of the corre-
sponding EC50 values were in the range of 0.71–1.2 ng/mL
and lower than the mean LSD Cmax values (1.3 and 3.1 ng/
mL for the 100- and 200-lg doses, respectively) observed
in the present study. ‘‘Bad drug effects’’ were moderate and
not present in every subject. Consistent with this finding,
the EC50 values were higher than those for ‘‘good drug
effect’’ and ‘‘any drug effect’’ (1.5–2.5 ng/mL). As previ-
ously reported, the subjective effects were dose dependent,
whereas the autonomic effects were comparable at both
doses [21]. When analyzed within subjects using pharma-
cokinetic-pharmacodynamic modeling, a close relationship
was found between plasma concentrations of LSD and the
effects of LSD, with moderate counterclockwise hysteresis.
Counterclockwise hysteresis typically reflects the time lag
that is caused by drug distribution to the effect site and the
response time associated with the mechanism of action.
The present study showed that the subjective and auto-
nomic effects establish themselves relatively slowly. On
average, the subjective ‘‘any drug effect’’ peak was reached
2.8 and 2.5 h after administration of the 100- and 200-lg
doses, respectively, and 1.1 and 0.6 h after the respective
peak LSD concentrations were reached. The lag times were
comparable for the increases in heart rate and blood pres-
sure but longer for the thermogenic response. No clockwise
hysteresis was found for any of the pharmacodynamic
outcome measures, and thus no evidence was found of
acute tolerance as described for other psychoactive sub-
stances, such as methylenedioxymethamphetamine [39] or
cocaine [40], or for repeated administration of LSD [41].
Thus, as long as relevant concentrations of LSD were
present in plasma, subjective and autonomic effects were
observed. The mean durations of the subjective effects of
LSD was 8 and 11 h after administration of the 100- and
200-lg doses, respectively, and the difference corre-
sponded to the plasma half-life of LSD.
The present analyses typically found no correlations
between LSD concentrations and the effects of LSD across
subjects within dose groups, likely because of the relatively
high concentrations of LSD and generally consistently high
subjective response ratings in most subjects. If relatively
high and similar doses of LSD are used that result in plasma
concentrations above the EC50 of a particular response
measures, then responses do not vary across subjects
because responses are close to maximal. This would typi-
cally also be the case with measures with a maximal effect
limit such as VAS ratings and some physiological effects
such as pupil size [42]. In fact, responses to LSD or other
drugs in a standardized experimental setting may vary only
if the response is not induced consistently in all subjects
(e.g., at the beginning and end of the response) because of
individual differences in drug absorption/distribution and
elimination. Correlations of plasma concentrations with the
subjective and cardiovascular effects of LSD or 3,4-
methylenedioxymethamphetamine [42] across subjects are
only weak during the peak response. This finding needs to
be considered when interpreting associations between sub-
jective responses and other measures, such as fMRI
parameters. fMRI findings may reflect the variance in LSD
plasma concentrations. The likelihood of detecting corre-
lations within a dose group increases for effects that are not
robustly induced in all subjects.
The present study has limitations. First, the two doses of
LSD were evaluated in two separate studies in different
participants and not within subjects. Second, the plasma
samples were analyzed in different laboratories. Nonethe-
less, the pharmacokinetic data were consistent across the
two studies and laboratories.
5 Conclusion
We gathered pharmacokinetic data for oral LSD that are
essential for interpreting the findings of clinical studies and
LSD intoxication. LSD had dose-proportional pharma-
cokinetics and first-order elimination up to 12 h. A close
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plasma concentration–effect relationship was found within
subjects over time, with moderate counterclockwise hys-
teresis because of a short lag of the response. Generally, no
association was found between plasma LSD concentrations
and its robust effects when analyzed across different sub-
jects and within a dose group. This has implications for
studies that interrelate different effects of LSD.
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